Medicare's LCD L37810 sets coverage rules for genomic sequence analysis panels used in solid organ tumors. The reader searching this exact phrase usually needs to know one of two things: whether a specific panel is covered for a specific cancer under this policy, or why a claim citing L37810 was denied. The policy, issued by Medicare contractor Palmetto GBA for Jurisdiction JJ, governs multigene panels rather than single-gene tests, and coverage depends on tumor type, panel composition, prior testing status, and documentation. This article explains how the determination works, what it covers and excludes, and the practical claim mechanics that decide whether an oncologist's genomic panel gets paid.
What LCD L37810 Governs and Which Medicare Jurisdiction Applies
Local Coverage Determination L37810 is a Palmetto GBA policy for Medicare Jurisdiction JJ covering genomic sequence analysis panels in the treatment of solid organ neoplasms. Jurisdiction JJ spans Alabama, Georgia, and Tennessee, plus a defined set of associated territories. A local coverage determination is contractor-issued policy, and it applies only to claims processed by that Medicare Administrative Contractor.
The scope matters because a clinician in another jurisdiction may follow a different LCD for the same test. Genomic panels ordered for a patient whose claim flows to a different MAC are not adjudicated under L37810. The policy's companion document is the related local coverage article, which carries the billing and coding instructions and the ICD-10 code lists for covered and non-covered diagnoses. That article changes more frequently than the LCD itself.
Coverage under L37810 attaches to the test and the clinical circumstance together. A covered panel used for an uncovered indication is a non-covered service. This dual gating is the single most common source of confusion for oncology practices billing these assays.
The policy classifies multigene genomic panels as tests analyzing multiple genes at once, using sequencing methods, to inform treatment decisions in solid tumors. Readers should verify the current effective and revision dates directly through the CMS Medicare Coverage Database, because contractor policies are revised and sometimes retired. This article describes the policy's structure and decision logic as of November 2026; it does not substitute for reading the current document.
Covered Indications: When a Genomic Panel Meets LCD Criteria
L37810 covers genomic sequence analysis panels when the test is used to guide treatment decisions for a solid organ neoplasm and the patient meets the policy's clinical criteria. Covered indications in the family of solid tumor LCDs typically include lung cancer, colorectal cancer, melanoma, and certain other solid tumors where the panel informs therapy selection. The exact covered list lives in the local coverage article's ICD-10 table.
The treatment-framing in the title is deliberate. This is a treatment determination, not a screening or general risk-assessment policy. That means the ordering documentation should establish that the patient has a diagnosed solid organ neoplasm and that results will change or confirm the therapeutic plan.
Most contractor LCDs of this type permit panels of defined gene content, typically in the range of a specified minimum and maximum number of genes. Panels larger than the policy's stated maximum generally fall outside the determination and are adjudicated as non-covered.
Diagnosed solid organ neoplasm, documented in the order Panel gene content within the policy's stated bounds Treatment decision as the stated purpose of the test Results expected to alter or confirm therapy selection
Coverage also depends on the panel being ordered by the treating oncologist or appropriate specialist. A pathologist-ordered panel for diagnostic classification may satisfy a different policy, not this one. That distinction alone accounts for a meaningful share of denials.
What L37810 Does Not Cover: Panels, Purposes, and Populations Outside the Policy
L37810 excludes panels used for screening asymptomatic patients, panels ordered for hereditary cancer risk assessment, and panels whose purpose is prognosis or recurrence monitoring outside treatment selection. It also excludes panels larger than the policy's stated maximum gene count.
Liquid biopsy assays, whole-genome sequencing, and whole-exome sequencing sit outside the determination. Those services may have separate coverage pathways or may be statutorily non-covered, but L37810 is not the authority for them. An order form that bundles a covered tissue panel with an uncovered add-on creates a billing split, not a single covered claim.
Watch the population boundary. Medicare coverage under a given LCD applies to Medicare beneficiaries meeting the criteria, and the policy does not convert to commercial coverage. Commercial and Medicare Advantage plans set their own medical policies, which may adopt, modify, or reject L37810's criteria entirely.
One frequent edge case: a patient switches from a Medicare Advantage plan to Original Medicare mid-episode, and the panel that was authorized under the plan's criteria now adjudicates under the MAC's LCD. Authorization obtained under the plan does not bind the MAC. Timeline and documentation should be rechecked at the point of service.
How the Policy Decides a Claim: Review, Documentation, and Medical Necessity
Claims citing L37810 pass through medical necessity review, which is where most denials originate. The reviewer asks whether the test, the tumor, and the documented treatment question all line up with the policy and its article. Absent that alignment, the service can be denied even when the panel itself is a recognized assay.
Documentation requirements are the practical core. The ordering record should name the solid tumor, state the treatment decision the panel informs, and show prior relevant testing where the policy expects it. If the policy's sequence expects single-gene testing first for certain biomarkers, a panel ordered without that history is vulnerable.
Step 1: Confirm the patient's claim is processed by Palmetto GBA in Jurisdiction JJ. Step 2: Match the tumor diagnosis to a covered ICD-10 code in the companion local coverage article. Step 3: Verify the panel's gene count and content sit within the policy's stated bounds. Step 4: Document the treatment decision the results will inform, in the order and progress note. Step 5: Record any prior single-gene or targeted testing and why a panel is now appropriate. Step 6: Confirm the performing laboratory's accreditation and that the assay is not investigational. Step 7: Submit with the correct CPT code for the panel size and retain the full report.
Failure handling follows from where the claim broke. Diagnosis mismatch means checking the article's code list before resubmission. Gene count outside bounds means either a different code or an appeal on medical necessity with the treatment rationale spelled out. Missing prior testing documentation means a corrected claim with the history attached. A redetermination request reopens the denial, and the documentation burden stays on the ordering clinician.
Gene Count and CPT Coding: Why Panel Size Drives Payment and Denial
Panel size drives both coverage under many solid tumor LCDs and the CPT code submitted. Genomic sequencing panels are reported by tier β roughly, panels of 5 to 50 genes, panels of 51 or more genes, and the large panels above 200 genes sit in different code families. The exact code set is maintained by the American Medical Association and updated annually through the CPT editorial process.
Tier 1 codes cover smaller, targeted panels Tier 2 codes cover larger panels with broader content Very large panels map to separate codes with their own coverage considerations
The mismatch that generates denials is a gene count in the report that does not match the code on the claim, or a panel that grew beyond the policy's stated maximum while still billed under a covered code. Laboratories sometimes expand assay content between versions; the code and the coverage basis must follow the current version.
Payment amount for a given code is not fixed in the LCD. It comes from the Medicare Physician Fee Schedule and Clinical Laboratory Fee Schedule depending on the code family, and the contractor's fee schedule shows the local amount. Readers should confirm the current payment rate through their MAC's fee schedule lookup rather than relying on any quoted figure, since rates reset annually.
Consider a worked example. A practice bills a 52-gene panel under the tier code for 51-plus genes for a lung cancer patient. If the policy's coverage criteria attach to that tier and the diagnosis code is on the article's list, the claim has a clean path. If the same laboratory adds 15 genes the following quarter without changing the code, the panel's content no longer matches the billed tier, and a review can deny on that discrepancy alone. The arithmetic is simple: the report's gene count and the code's gene range must agree.
Companion Local Coverage Article: Codes, ICD-10 Matching, and Updates
The related local coverage article is the operational half of L37810. It carries the covered ICD-10-CM diagnosis list, the covered CPT codes, and any documentation requirements stated in billing language. A claim can meet the LCD's clinical logic and still fail because the diagnosis code is absent from the article's covered list.
Updates to the article happen on a separate cycle from the LCD. CMS's Medicare Coverage Database posts both documents and their revision histories, and contractors issue notice when articles are revised. Practices that hard-code diagnosis lists into their order forms should treat the article's list as a living document.
The ICD-10 matching task deserves its own check. A lung cancer claim coded to a secondary malignancy site rather than the primary, or a neoplasm coded as uncertain behavior, may fall outside the covered list even though the clinical picture fits the LCD. Coders should verify the exact code against the current article before submission.
The article also resolves which code applies when a claim spans a panel and an add-on service. That coding guidance is where bundled-versus-separate reporting decisions get made, and it is the section most worth reading in full for billing staff.
Prior Testing and Sequencing Rules That Sink Otherwise Valid Claims
Many solid tumor LCDs embed a sequencing expectation: for certain biomarkers with established single-gene or targeted tests, the policy anticipates that targeted testing has been considered or performed before a broader panel. A panel ordered as first-line testing for a biomarker with a validated targeted assay can draw a medical necessity denial under that logic.
The rationale is resource stewardship. A common alteration with a cheap, fast targeted test doesn't require a large panel to detect, and the contractor's criteria reflect that. When the clinical question genuinely requires broad content β for example, a tumor with no established single-driver target β the panel is the appropriate test, and the documentation should say so.
Was targeted testing for the relevant biomarker performed or considered? If not, what clinical feature makes broad panel testing the right next step? Are the expected results actionable for this patient's treatment at this stage?
Edge scenario: a patient with a progressing tumor after first-line therapy and no remaining tissue for sequential testing. The clinician orders a broad tissue panel because repeat biopsy is not feasible. That is a defensible medical necessity argument, but it has to be written down. A denial on sequencing grounds often gets reversed at redetermination when that rationale is supplied.
Jurisdiction Limits, Plans, and What Changes for Non-Medicare Payers
L37810 binds Palmetto GBA's Medicare claims in Jurisdiction JJ only. Other MACs publish their own solid tumor genomic panel LCDs, often with similar structure and different specifics β different gene count ranges, different covered diagnosis lists, different effective dates. A test covered in one jurisdiction can be non-covered in another.
Medicare Advantage plans are a separate matter. These plans follow CMS coverage rules where a national or local coverage determination exists, but they administer their own medical policies and prior authorization processes. A plan may apply L37810's criteria or its own. Authorization numbers from a plan do not transfer to Original Medicare, and the reverse is also true.
Commercial payers set their own policies entirely. Many use published criteria from professional societies or their own medical policy bulletins, and their panel size thresholds, prior authorization requirements, and documentation expectations can differ from any Medicare LCD. Practices running mixed payer mixes should maintain a per-payer grid rather than a single genomic testing workflow.
State-level variation also enters through laboratory licensure and through Medicaid programs, which may adopt Medicare criteria, modify them, or set separate rules. The operational takeaway: treat L37810 as the rulebook for one lane, and confirm the rulebook for every other lane before the order goes out.
Cost, Denial Risk, and Appeal Economics for Genomic Panels
The financial exposure from a genomic panel claim is asymmetric. A denied panel can leave the laboratory or the practice holding a four-figure or higher charge, and the appeal consumes staff time that is rarely reimbursed. That makes front-end verification cheaper than back-end appeal in nearly every case.
Build the cost picture from attributed figures rather than guesses. Panel payment rates come from the applicable Medicare fee schedule for the billed code, and the contractor's fee schedule shows the local rate; confirm the current amount through Palmetto GBA's fee schedule lookup. Appeal cost is internal: staff hours multiplied by loaded wage, plus the clinical time to document medical necessity.
Front-end verification cost: minutes of coder and clinician time per order Denial cost: full charge held, plus redetermination staff time Appeal win rate: varies by denial reason, so track your own by category
A simple computation shows why the front end wins. If a practice submits 40 panels a month and 10 percent draw medical necessity denials, that is four denials monthly. If each appeal takes two staff hours at a loaded rate of $45 per hour, the monthly appeal labor runs about $360 before any clinical time. Compare that with a five-minute verification step per order: roughly 200 minutes, or about 3.3 staff hours monthly. The verification step costs less than the appeals it prevents, and it also prevents the revenue delay.
Failure mode to watch: panels ordered under a standing protocol that hasn't been updated since the article's last revision. The protocol passes orders that the current code list no longer covers, and denials cluster around one diagnosis code. Audit the protocol against the article quarterly.
FAQ
Does L37810 cover a 500-gene panel?
Generally no, if the panel exceeds the policy's stated maximum gene count. Very large panels fall outside the determination and adjudicate as non-covered unless a separate coverage basis applies. Confirm the panel's current size against the companion article's covered code list, because laboratories expand assay content between versions without changing the order name. A panel that grew past the threshold needs a different coverage argument, not the same claim resubmitted.
Is L37810 the same as a national coverage determination?
No. A national coverage determination is issued by CMS and binds all Medicare contractors. L37810 is a local coverage determination issued by Palmetto GBA for Jurisdiction JJ. The practical consequence is portability: the same test ordered for a patient whose claim processes in another jurisdiction is judged under that contractor's policy, which may differ in covered diagnoses, gene count limits, and documentation expectations.
Why was my panel denied when the patient clearly has cancer?
The most common cause is a diagnosis code that isn't on the companion article's covered list, even though the clinical diagnosis is correct. Coding to a secondary site, an uncertain-behavior neoplasm, or a code added after the article's last revision can trigger this. Check the exact ICD-10 code against the current article before resubmission, and attach the pathology report with a corrected claim.
Does prior authorization from a Medicare Advantage plan guarantee payment under L37810?
No. Plan authorization binds the plan, not the Medicare Administrative Contractor. If the patient moves to Original Medicare or the claim processes under the MAC, the LCD's criteria apply independently. Re-verify diagnosis, gene count, and documentation at the point of service, because an authorization number from another payer does not travel with the claim.
How often does the local coverage article change?
More often than the LCD itself, and on a separate cycle. CMS's Medicare Coverage Database posts revision histories for both documents, and contractors issue notice of revisions. Practices that embed diagnosis lists in order forms should review the article at least quarterly and after any announced revision. Hard-coded lists are a leading cause of clustered denials.
Can a commercial payer adopt L37810's criteria?
Yes, some do, but adoption is voluntary and partial. Commercial and Medicare Advantage plans publish their own medical policies, which may mirror the LCD's gene count thresholds or use entirely different criteria from professional society guidance. Never assume alignment. Check each payer's policy bulletin for the specific panel code before ordering, especially for panels above 50 genes.
What happens if the laboratory's assay is investigational?
Panels classified as investigational are excluded regardless of whether the clinical scenario fits the LCD. The performing laboratory's accreditation and the assay's status matter to coverage, and a claim can fail on that basis even with perfect clinical documentation. Confirm the assay's status with the laboratory before ordering, and route investigational testing through a clinical trial or registry pathway instead of a coverage claim.
Does a denial mean the test wasn't medically necessary?
Not necessarily. Denials under this policy most often reflect a documentation or code mismatch rather than a clinical judgment that the test was inappropriate. A redetermination request with the treatment rationale, prior testing history, and corrected coding can reverse a denial. Track denial reasons by category to see whether the pattern is clinical or administrative.
This article is general educational information about Medicare coverage policy and is not a diagnosis, treatment plan, billing guarantee, or legal opinion. Coverage determinations change and vary by contractor, plan, and patient, so confirm current policy through the CMS Medicare Coverage Database, your Medicare Administrative Contractor, and the payer before ordering or billing. Consult a qualified billing professional or compliance officer for claim-specific decisions, and for immediate medical concerns contact a local clinician or emergency services.